- Investing.com
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Metrics to compare | VETO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVETOPeersSector | |
---|---|---|---|---|
P/E Ratio | 18.4x | 16.7x | −0.6x | |
PEG Ratio | −0.93 | 0.03 | 0.00 | |
Price/Book | 1.6x | 2.2x | 2.6x | |
Price / LTM Sales | 1.6x | 2.9x | 3.1x | |
Upside (Analyst Target) | 22.1% | 29.3% | 52.1% | |
Fair Value Upside | Unlock | 6.3% | 8.2% | Unlock |